ARVO 2024: Researchers detail novel glaucoma shunt

Author(s):

In a presentation at the Association for Research in Vision and Ophthalmology 2024 annual meeting in Seattle, researchers detailed a novel shunt, which could potentially improve postoperative IOP control and lower the risk of vision-threatening issues.

(Image credit: Adobe Stock)

In a study presented this week at the Association for Research in Vision and Ophthalmology (ARVO) 2024 annual meeting in Seattle, a team of researchers introduced a new type of shunt for treating glaucoma that can be adjusted after surgery to control how much fluid flows out of the eye.

According to a news release, this novel shunt could potentially improve postoperative IOP control and lower the risk of vision-threatening issues^.1

Ariana Levin, MD, from New York University, along with researchers from Myra Vision in California and the John A. Moran Eye Center in Utah, at ARVO presented a novel shunt that can be opened or closed with a laser.

Levin noted in the news release that researchers developed a novel titratable aqueous shunt for glaucoma therapy designed to allow physicians to increase or decrease the flow of aqueous fluid through the shunt in a slit lamp-based laser procedure.¹

“The potential to control aqueous fluid in the postoperative period may allow physicians to personalize care for every patient and potentially improve the safety and efficacy of glaucoma surgery,” she said in the news release.